Recor Medical Unveils Innovations in Hypertension Management for World Hypertension Day 2026

In honor of World Hypertension Day 2026, observed on May 17th, Recor Medical, Inc., a subsidiary of Otsuka Medical Devices, takes a significant step to raise awareness about hypertension and its treatment advancements. This day brings to light the critical issue of high blood pressure, which affects over one billion individuals globally and remains a primary cause of serious cardiovascular diseases.

Hypertension, often referred to as the 'silent killer', has seen a staggering increase in prevalence, with the World Health Organization reporting that numbers jumped from 650 million in 1990 to approximately 1.3 billion in 2019. This sharp rise underscores the urgent need for effective treatments and greater awareness to combat this global health challenge. Unfortunately, many patients struggle with uncontrolled hypertension even after adopting healthier lifestyles and utilizing medications. This highlights a clear need for more innovative treatment approaches.

Emphasizing Early Detection

This year's theme, "Controlling Hypertension Together", stresses the importance of early detection and ongoing management to enhance life quality and expectancy. Helen Reeve-Stoffer, COO of Recor Medical, emphasizes the need to bridge the gap between diagnosis and effective management. She asserts that the company is dedicated to advancing groundbreaking solutions that go beyond conventional therapies, thereby enhancing physician capabilities in managing patients with uncontrolled blood pressure.

Dr. Shon Chakrabarti, Recor Medical's Chief Medical Officer, reinforces this message, asserting that hypertension represents one of the most significant modifiable risk factors in medicine that remains often under-diagnosed and under-treated. The introduction of new technologies and treatments like device-based therapies could herald a new era in hypertension care, enabling better control of blood pressure alongside traditional medications.

Introducing the Paradise uRDN System

At the forefront of these innovations is the Paradise™ ultrasound renal denervation (uRDN) system. This minimally invasive therapy seeks to address overactive sympathetic nerve activity contributing to hypertension. The technology employs ultrasound energy to calm the overactive renal nerves, unveiling a promising adjunct treatment for suitable patients.

The Paradise uRDN system administers doses of 360-degree ultrasound energy around the renal arteries, using a specialized HydroCooling™ system to protect the artery walls during the procedure. Clinically validated, the system received FDA approval in November 2023, marking a significant advancement in hypertension management. Dr. Chakrabarti anticipates that integrating such technologies will expand treatment options, aiding countless patients in achieving meaningful blood pressure reductions.

With clinical trials yielding positive outcomes and the initiation of the Global Paradise System (GPS) Registry to generate real-world evidence, Recor Medical's commitment to addressing hypertension is evident. Ongoing research and patient engagement are pivotal to ensuring that innovative solutions reach those most in need, ultimately saving lives.

Conclusion

As we recognize World Hypertension Day in 2026, the collective efforts of companies like Recor Medical aim to not only increase awareness regarding hypertension but also revolutionize how it is managed worldwide. The collaboration in detection, treatment, and patient education will be essential in combating this grave global health concern. With continued innovation, we can provide hope to millions suffering from this condition, ensuring healthier futures.